



HAL
open science

NOD2 dependent signalling exacerbates the intestinal epithelium injury and limits murine Norovirus propagation

Ghaffar Muharram, Marion Thépaut, Pierre-Emmanuel Lobert, Teddy Grandjean, Olivier Boulard, Myriam Delacre, Emmrich Wakeford, Richard Wheeler, Lionel Franz Poulin, Ivo Gomperts Boneca, et al.

► **To cite this version:**

Ghaffar Muharram, Marion Thépaut, Pierre-Emmanuel Lobert, Teddy Grandjean, Olivier Boulard, et al.. NOD2 dependent signalling exacerbates the intestinal epithelium injury and limits murine Norovirus propagation. 2022. hal-03909060

HAL Id: hal-03909060

<https://hal.science/hal-03909060v1>

Preprint submitted on 21 Dec 2022

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

1 **NOD2 dependent signalling exacerbates the intestinal epithelium injury and limits**
2 **murine Norovirus propagation**

3

4 **Authors:** Ghaffar Muharram^a, Marion Thépaut^a, Pierre-Emmanuel Lobert^c, Teddy
5 Grandjean^a, Olivier Boulard^b, Myriam Delacre^a, Emmrich Wakeford^a, Richard Wheeler^c,
6 Lionel Franz Poulin^b, Ivo Gomperts Boneca^c, Frank Lafont^a, Marie-Cécile Michallet^d, Didier
7 Hober^c, Ken Cadwell^{f,g,h}, Mathias Chamaillard^b.

8 **Affiliations :**

9 ^aUniv. Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019 - UMR 9017 - CIIL -
10 Centre d'Infection et d'Immunité de Lille, F-59000 Lille, France.

11

12 ^bLaboratory of Cell Physiology, INSERM U1003, University of Lille, Lille, France.

13 ^cUniv Lille, Faculté de Médecine, CHU Lille, Laboratoire de Virologie ULR3610, Lille,
14 France.

15

16 ^dTERI (Tumor Escape, Resistance and Immunity), Centre de recherche en cancérologie de
17 Lyon, Centre Léon Bérard, Université de Lyon, Université Claude Bernard Lyon 1, Inserm
18 1052, CNRS 5286, 69008 Lyon, France.

19

20 ^eInstitut Pasteur, Université Paris Cité, CNRS UMR6047, INSERM U1306, Unité de Biologie
21 et génétique de la paroi bactérienne, F-75015, Paris, France

22

23 ^fKimmel Center for Biology and Medicine at the Skirball Institute, New York University
24 Grossman School of Medicine, New York, NY 10016, USA

25 ^gDepartment of Microbiology, New York University Grossman School of Medicine, New
26 York, NY 10016, USA

27 ^hDivision of Gastroenterology and Hepatology, Department of Medicine, New York
28 University Langone Health, New York, NY 10016, USA

29

30

31 **Disclosure of interest:**

32 K.C. has received research support from Pfizer, Takeda, Pacific Biosciences, Genentech, and Abbvie;
33 consulted for or received honoraria from Vedanta, Genentech, and Abbvie; and holds U.S. patent
34 10,722,600 and provisional patent 62/935,035 and 63/157,225.

35 **Correspondence should be addressed to:**

36 Mathias Chamaillard, PhD, Phone number: +33359317427, Fax number: +33359317480, E-
37 mail: mathias.chamaillard@inserm.fr

38 Ghaffar Muharram, PhD, phone number: +33320871033, E-mail:
39 ghaffar.muhammad@pasteur-lille.fr

40

41 **Key words:** NOD2, Norovirus, Inflammation, Colitis, Macrophages, Signalling.

42

43 **Data availability statement:** the data that support the findings of this study are available
44 from the corresponding author, GM or MC, upon request on HAL

45

46

47

48 **Abstract.** Over 90% of epidemic nonbacterial gastroenteritis are caused by human
49 Noroviruses (NoV) which are persisting in a substantial subset of people allowing their spread
50 worldwide. It leads to a significant number of endemic cases and up to 70,000 children deaths
51 in developing countries. NoVs are primarily transmitted through the fecal-oral route. To date
52 studies have focused on the influence of the gut microbiota on viral clearance by enteric
53 immunity. In this study, the use of the persistent mouse Norovirus S99 strain (MNoV_S99)
54 allowed us to provide evidence that bacterial sensing by nucleotide-binding oligomerization
55 domain 2 (Nod2) promotes the noroviral associated pro-inflammatory pathology in a dextran
56 sodium sulphate induced colitis mouse model. By contrast, the establishment of the pathology
57 in the colon is improved in the absence of Nod2. We also show in our cellular models a
58 greater phosphorylation of Signal Transducer and Activator of Transcription1 (STAT1) in
59 macrophages infected by MNoV_S99 when compared with mock-infected cells. This
60 increased STAT1 phosphorylation is associated with an induction of NOD2 expression in
61 macrophages. This in turn enhances myeloid cells response to muramyl dipeptide (MDP)
62 resulting in downstream pro-inflammatory cytokine secretion. Hence, our results uncover a
63 previously unidentified virus-host-bacterial interplay that is particularly important for
64 protecting against several common illnesses, such as Crohn's disease.

65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80

81 **Introduction.** With the development of high throughput sequencing techniques, we are
82 progressively gaining a better knowledge of the composition of the enteric virome (ensemble
83 of gut virus communities)¹. This is of particular importance for unravelling the pathogenesis
84 of viruses that are establishing persistent infections^{2,3}. Amongst enteric viruses yielding pro-
85 inflammatory phenotypes, noroviruses (NoV) are responsible for the majority of non-bacterial
86 gastroenteritis worldwide. **These** single stranded RNA (+) viruses, belonging to the family of
87 *Caliciviridae* have been studied for several years. Until recent progress in cultivation methods
88 of **noroviruses from** genogroups I, II, IV, VIII and IX⁴⁻⁶ **that infect humans** (HuNoVs),
89 mechanistic details were mostly obtained from studies using the mouse norovirus (MNoV)⁷.
90 **Indeed, MNoVs** can be easily produced *in vitro* in macrophages or dendritic cells⁸. Several
91 MNoV strains have been described based on their shedding time in the stool and classified as
92 persistent or acute (non-persistent) strains⁹.

93 **Multiple intracellular pattern recognition receptors (PRR) have been associated with indirect**
94 **noroviral detection, especially during NoV genome replication, when double stranded RNA**
95 **intermediates are generated**¹⁰. The Toll like receptor 3 (TLR3) that recognizes any dsRNA in
96 the endosomal compartment and the melanoma differentiation associated protein-5 (MDA-5),
97 a member of the RIG-I like receptor (RLR) family that recognizes long dsRNA, have been
98 shown to participate in the detection of the MNoV_1 strain and its plaque isolate the
99 MNoV_CW3¹¹. Amongst the Nod like receptor (NLR) family, Nlrp6 was shown to bind with
100 the encephalomyocarditis virus (EMCV), a single strand RNA (+) enteric virus, via the RNA
101 helicase Dhx15. Following the formation of these complexes, interferon (IFN) type I and III
102 signalling responses are triggered via the recruitment of the mitochondrial antiviral signalling
103 (MAVS) protein. Interestingly, this study also showed that, Nlrp6^{-/-} mice infected with
104 MNoV_1 had higher viremia, suggesting similar mechanisms of NoV sensing by Nlrp6¹².
105 Another member of the NLR family, the nucleotide-binding oligomerization domain 2

106 (NOD2) mostly known as a sensor of muropeptides from Gram positive and negative
107 bacteria¹³, was also shown to directly bind with the genome (ssRNA-) of the respiratory
108 syncytial virus (RSV) to induce antiviral responses¹⁴. The recruitment of MAVS by NOD2
109 was needed to activate the interferon-regulatory factor 3 (IRF3) dependent signalling and
110 provoke IFN- β production. So far, no PRR has been identified as a direct sensor of
111 noroviruses. However, NOD2 dependent signalling was shown to potentiate gut inflammation
112 and increase lethality in an *E. Coli* and MNoV_1 co-infection mouse model¹⁵.

113 Another molecular player that is essential to activate antiviral signalling is the cytosolic
114 protein signal transducer and activator of transcription 1 (STAT1). MNoV_1 infections were
115 shown to be lethal in STAT1 knock-out mice¹⁶. And STAT1 dependent interferon responses
116 were shown to limit MNoV_1 replication and dissemination *in vivo*¹⁷.

117 Owing to the variety of circulating NoV strains, strain-dependent effects are expected to occur
118 and should be studied more in details. Even a single amino acid change in the NS1/2 viral
119 protein is sufficient to switch the acute MNoV_CW3 strain to a persistent state¹⁸, showing the
120 high degree of adaptability of NoV genomes and hence their versatility to counteract host
121 defence mechanisms. Type III interferon (IFN- λ) response has been shown to control the *in*
122 *vivo* propagation of the persistent MNoV_CR6 strain¹⁹, while type I and II interferons
123 mediate innate immune responses against acute MNoV infections^{16,20}.

124 Interestingly, Cadwell and colleagues have demonstrated how infection with the MNoV
125 persistent strain CR6 rendered *Atg16l1*^{HM} mice more susceptible to dextran sodium sulphate
126 (DSS)-induced colitis²¹. Functional autophagy is critical for microbial elimination. And
127 NOD2's interaction with ATG16L1 was shown to regulate the autophagy clearance of
128 pathogenic bacteria²². Improper detection of microbial content in the digestive tract leads to
129 intestinal inflammation²³ and loss-of-function point mutations of either *NOD2* or *ATG16L1*
130 predispose humans to Crohn's disease^{24,25}. Insights into the mechanisms of how the loss of

131 tolerance of NOD2 against gut microbial communities can lead to uncontrolled
132 proinflammatory signalling are still missing.

133 In this study, we have investigated the underlying mechanism of the pathogenesis of the
134 persistent MNoV strain S99 (*Berlin*)²⁶. MNoV_S99 dependent inflammatory response to DSS
135 was compared in WT vs *Nod2*^{-/-} mice. NOD2-dependent signalling pathways activation was
136 further examined in response to MNoV_S99 during early or prolonged times of infection in
137 Raw264.7 cell line, bone marrow derived macrophages, monocytes and dendritic cells.
138 Finally, we have evaluated whether the priming effect of MNoV_S99 can fine-tune *Nod2*
139 dependent pro-inflammatory signalling.

140

141

142 **Results.**

143 **MNoV_S99 exacerbates the DSS-induced inflammation**

144 Since MNoV_S99 is a natural strain commonly found in animal facilities that is able to
145 establish persistent infections²⁶, we decided to assess MNoV_S99's implication in the
146 vulnerability to inflammatory responses of the intestinal mucosa. Hence, we examined
147 MNoV_S99's impact in a chemically-induced colitis model. C57BL/6J mice were first
148 infected with a single dose of 10⁷ TCID₅₀PFU/mL of MNoV_S99 or mock-treated with PBS.
149 One week later, drinking water was replaced with either a 3% DSS or 5% DSS solution for a
150 period of seven consecutive days (Fig. 1A). Weight-loss was monitored on a daily basis. **With**
151 **both concentrations of DSS, the pre-treatment with MNoV_S99 had induced a more**
152 **significant weight loss (purple and orange curves Fig. 1B and C).** After 7 days of DSS
153 treatment, mice were sacrificed. Histological analysis of colon sections revealed an increased
154 infiltration of inflammatory cells and epithelial damage in infected mice treated with DSS
155 when compared to similarly challenged animals that were not infected (Fig. 1D). Next, we

156 quantified the muscle thickness from these colon sections. An increased thickness was
157 measured in mice treated with the virus in presence of both 3 and 5% DSS in comparison with
158 Mock-treated control mice (Fig. 1E). Similarly, histological scoring of the haematoxylin and
159 eosin (H&E) stained colonic sections expectedly showed significantly more severity in mice
160 treated with MNoV_S99 + 3% or 5% DSS than DSS alone (Fig. 1F). Upon mice sacrifice,
161 resected colons were measured. A significantly reduced length was obtained in mice infected
162 with MNoV_S99 and treated with 5% DSS in comparison with non-infected control animals
163 (PBS) (Fig. 1G). The increased level of colitis was also evidenced by a significantly
164 augmented secretion of the pro-inflammatory cytokine interleukin-6 (IL-6) in the supernatants
165 of over-night *in vitro* cultured colon explants from MNoV_S99 infected + 5% DSS treated
166 mice versus those from DSS only mice (Fig. 1H). Taken together, these data clearly show a
167 much worse inflammation state in mice infected with MNoV_S99 in our chemically induced
168 colitis model.

169

170 **MNoV_S99 associated inflammation is abrogated in *Nod2*^{-/-} mice**

171 In cells from the myeloid lineage, NOD2 was shown to participate in the sensing of
172 *Citrobacter rodentium* and of commensal bacteria that are translocating in response to
173 chemically-induced epithelial injury²⁷. To determine whether NOD2 is also implicated in the
174 immunopathology of MNoV in our preclinical model of colitis, we compared the severity of
175 DSS-induced colitis in the presence of MNoV_S99 or not between WT and *Nod2*-deficient
176 mice. In contrast to what was observed in WT mice (Fig. 2A), the sensitizing effect of the
177 virus on the daily weight-loss was absent upon MNoV_S99 infection of *Nod2*^{-/-} mice (Fig.
178 2B). These data suggest that the pro-inflammatory effect of MNoV_S99 observed in WT
179 mice is a consequence of a loss of tolerance to bacterial MDP. Indeed, DSS induces an
180 abrasion of the epithelial barrier allowing commensal bacteria to cross the mucosa and

181 unleash a pro-inflammatory response from *Nod2* expressing cells. This was further confirmed
182 after mice were autopsied. Colon tissue sections staining confirmed the decreased levels of
183 colonic inflammation from MNoV_S99 infected *Nod2*^{-/-} vs WT mice (Fig. 2C). In agreement,
184 muscle thickness quantification from these colon sections showed significantly increased
185 thickness in MNoV_S99-infected WT mice under 3% DSS treatment vs 3% DSS alone (Fig.
186 2D). While in *Nod2*^{-/-} mice subjected to similar conditions, the excess of inflammation caused
187 by the viral infection was lost. Consequently, the variations of colon length measurements
188 that were induced upon MNoV_S99 infection were absent in *Nod2*^{-/-} mice when compared to
189 WT infected mice (Fig. S1A). Similarly, differences in histological scores measured from
190 MNoV_S99-infected WT mice vs DSS alone were also lost in *Nod2*^{-/-} infected mice (Fig.
191 S1B). And we could observe a clear trend in the increased levels of secretion of Tumour
192 necrosis factor α (TNF α) in the supernatants of *in vitro* cultured colon explants from WT
193 mice infected with MNoV_S99 and treated with 3% DSS vs those with DSS only. This effect
194 was absent in the supernatants from *Nod2*^{-/-} mice infected and treated similarly (Fig. S1C).
195 Overall, these data show the importance of bacterial sensing by NOD2 and the excessive
196 inflammatory response measured in the presence of MNoV_S99 in our DSS-induced colitis
197 mouse model.

198 **MNoV_S99 associated inflammation relies on NOD2 associated signalling**

199 Mouse noroviruses are known to have a tropism for the myeloid cell lineages, namely
200 macrophages and dendritic cells. Recently it was shown that Tuft cells belonging to the gut
201 epithelial cellular lineages, that possess the CD300lf MNoV receptor can also be targeted by
202 the MNoV_CR6 strain²⁸.

203 Making use of the GFP-Nod2 reporter mice line, we first examined in which cellular lineages
204 *Nod2* is expressed. We failed to observe GFP-Nod2 expression in epithelial cells, while
205 plenty of signal was detectable in the bulk of the cells bellow the lamina propria where

206 myeloid cells are located (Fig. 3A). Hence, our investigations regarding NOD2 expression
207 variations in response to MNoV_S99 infection focused on macrophages and monocytes in our
208 *in vitro* cellular models.

209 Interferon production being one of the most common response to the intracellular presence of
210 RNA genomes of foreign origin, we examined if the STAT1 signalling pathway that lays
211 upstream of ATG1611-mediated interferon production was activated in response to murine
212 norovirus infection.

213 To this end, bone marrow derived macrophages (BMDM) from WT mice were infected with
214 several MNoV strains at a multiplicity of infection (Moi) of 1, for 1h and pSTAT1 levels of
215 expression from cell lysates were measured by western blot (Fig. 3B). In contrast to the non-
216 persistent strain MNoV_CW3 that caused a striking increase in pSTAT1 level, the persistent
217 strains S99 and CR6 infections induced a much milder STAT1 signalling pathway activation.
218 The CW1 strain was associated with the lowest level of activation. Since MNoV_S99 is a
219 natural strain commonly found in animal facilities that is able to establish persistent
220 infections, we further analysed the mechanistic details behind its infection in our cellular
221 models.

222 Using the macrophage cell-line Raw264.7, we confirmed that MNoV_S99 is able to induce
223 phosphorylation of STAT1 (Tyrosine 701) at different times at Moi 1 (Fig. S3). pSTAT1 was
224 detectable as early as 15 minutes post-infection and its expression further increased at 30 min
225 and 1h, while total STAT1 was detectable in control non-infected cells and its expression only
226 slightly increased at later time-points. In addition to the STAT1 activation through the Janus
227 kinases JAK1 and Tyk2, we also examined the status of NF κ B activation, another pro-
228 inflammatory signalling pathway. For this purpose, pI κ B α levels were quantified from
229 infected cell lysates. Despite basal low-level activation in mock-infected cells, pI κ B α
230 intensity increased slightly at 30 min and 1h post-infection. However, no significant increase

231 was measured. When checking PI3K-AKT or the MAPK-ERK signalling axes **in the same**
232 **time frame**, MNoV_S99 failed to induce any activation of these signalling pathways (**Fig.**
233 **S2**). Next, we analysed the response of BMDM derived from WT or *Nod2*^{-/-} mice that were
234 infected with increasing doses of MNoV_S99 for 30 or 60 minutes (Fig. 3C). STAT1
235 activation increased over the course of the acute infection in cells derived from WT mice. In
236 contrast, the levels of pSTAT1 were barely detectable in *Nod2*^{-/-} cells at Moi 1. However, at a
237 higher dose (Moi 5), Nod2-dependent STAT1 activation was only observable at the 30
238 minutes time point. At 60 minutes post-infection, the decrease in pSTAT1 levels in response
239 to MNoV_S99 infection was not significant anymore when compared with WT cells.

240 Next, we examined if Stat1 activation was detectable after prolonged times of infection.
241 Indeed, we measured significant differences in pStat1 expression levels between WT and
242 *Nod2*^{-/-} MNoV_S99-infected cells 24h post-infection at Moi 0.1 (Fig. 3D).

243 To examine whether the Mitochondrial antiviral signalling (MAVS) adaptor protein is
244 required for sensing MNoV_S99, BMDM derived from Mavs-deficient mice were compared
245 to WT cells. Interestingly, the higher pStat1 levels measured in WT cells (Moi 0.1, 1h) were
246 significantly decreased in cells derived from *Mavs*^{-/-} cells (Fig. 3E).

247 Altogether, these data show a mild but significant activation of pro-inflammatory signalling
248 pathways following MNoV_S99 infection in our *in vitro* cellular models. These signalling
249 responses can be at least partially abrogated in the absence of MAVS and NOD2.

250

251 **MNoV_S99 persistence is decreased with loss of tolerance to Bacterial MDP**

252 To investigate the mechanisms behind the excessive inflammatory response induced by
253 MNoV_S99 infection in our *in vivo* experiments, we further explored how NOD2 expression
254 levels were affected by the viral infections.

255 NOD2 expression was determined by RT-qPCR in Raw264.7 cells or BMDM derived from
256 WT mice treated with MNoV_S99. Interestingly, NOD2 expression levels are significantly
257 increased in response to the viral infection in both cellular models (Fig. 4A and 4B).

258 Thus, augmented NOD2 expression plus STAT1 activation following MNoV_S99 infection
259 suggests a proinflammatory signalling loop, that could **ultimately** limit viral propagation on
260 one hand and induce increased levels of inflammation on the other hand. **The norovirus**
261 **induced NOD2 up-regulation** could explain the viral-induced pathogenesis that we observed
262 in our colitis model.

263 **Accordingly, when we analyzed the viral replication in BMDM derived from WT or *Nod2*^{-/-}**
264 **mice infected *in vitro* with MNoV_S99 (Moi 0.1 for 24h), the quantity of viral genomes was**
265 **significantly lower in the WT cultures (Fig. 4C).**

266 **Several reports in the literature have shown an interplay between gut microbiota composition**
267 **and the intestinal epithelium that modulates the interferon response that in turn favors MNoV**
268 **infection especially for the MNoV_CR6 persistent strain¹⁹. WT and *Nod2*^{-/-} mice were**
269 **co-housed for 4 weeks before we measured the viral load in stools by RT-qPCR after RNA**
270 **extraction. In line with our *in vitro* data on viral replication in BMDM, we could not detect**
271 **any viral genome in stools from non-cohoused WT mice (Fig. 4D). $5.49 \cdot 10^2 \pm 1.78 \cdot 10^2$ mean**
272 **(\pm sem) genome copies numbers were measured in *Nod2*^{-/-} mice co-housed with WT mice and**
273 **$4.12 \cdot 10^2 \pm 2.63 \cdot 10^2$ in WT mice co-housed with *Nod2*^{-/-} animals. These preliminary results**
274 **need to be further explored but they hint towards the hypothesis that the knock-out of NOD2**
275 **favors the multiplication of one or more phylum of the gut microbiota that in turn allows a**
276 **prolonged persistence of MNoV_S99.**

277 In order to have a better comprehension of how these dual stimuli are articulated together, we
278 examined Stat1 and I κ B α signalling pathways activation in response to MNoV_S99 infection
279 followed by secondary MDP (commonly expressed by all bacteria) treatment in monocytes

280 isolated from WT mice. As previously shown with BMDM or Raw264.7 cells, MNoV_S99
281 infection did also induce Stat1 activation (Fig. 4E and 4F) in monocytes. Similarly, IκBα was
282 not activated by the viral infection alone. Though, relatively high basal levels were already
283 detectable in mock-infected cells. As expected the treatment with the peptidoglycan MDP
284 alone triggered potent IκBα activation without activating Stat1 (Fig. 4E, MNoV_S99-, MDP+
285 condition). Interestingly, while IκBα activation by single MNoV_S99 infection was not
286 achievable (Fig. 4E, MNoV_S99+, MDP- condition), MNoV_S99 infection followed by
287 secondary MDP treatment was associated with both pathways' moderate but significant
288 activation (Fig. 4F, MNoV_S99+, MDP+ vs mock treated cells).

289 **Similarly, we noticed a significantly augmented pro-inflammatory cytokine TNFα response to**
290 **MDP in dendritic cells that were first primed with Noroviral RNA (Fig. 4G).**

291 Finally, we compared WT and *Nod2*^{-/-} derived BMDM cultures' TNFα response to
292 MNoV_S99 infection followed by MDP treatment. TNFα levels were increased with
293 increasing doses of virus in WT cells, while they remained undetectable (Moi 0.1) or much
294 lower (Moi 1) in *Nod2*^{-/-} cells (Fig. 4H).

295 Overall, these *in vitro* data fit nicely with our *in vivo* models where excessive bacterial-
296 induced inflammatory responses were observed when mice were infected with MNoV_S99
297 and treated with DSS. The increase in *Nod2* transcription levels in response to noroviral
298 infection favours in turn excessive inflammatory signalling pathways activation. This suggest
299 that MNoV_S99 induces a loss of tolerance to bacterial MDP **in WT mice.**

300

301 **Discussion**

302 The breach in gut flora homeostasis termed dysbiosis is becoming central in the onset of
303 chronic inflammatory bowel disease, such as Crohn's disease^{29,30}. With the development of
304 molecular biology techniques, alterations in the virome relevant to disease pathogenesis are

305 thoroughly under investigation². The cytosolic sensor NOD2 is very well known for its
306 pathogen associated molecular pattern recognition activity against bacteria¹³, and recently it
307 appears it can also participate in detection of certain viruses¹⁴. Hence, the combination of
308 genetic susceptibility factors and opportunistic viral infections could be one of the triggers of
309 CD³¹. Using pro-inflammatory signalling activation downstream of NOD2 as a read-out, we
310 have analysed if NOD2 can also participate in MNoV detection. All our *in vitro* experiments
311 with monocytic lineage derived primary cells (e.g. BMDM, BMDC and BM) and cell line
312 (e.g. Raw264.7) infected with different MNoV strains showed activation of the STAT1
313 signalling pathway implicated in the pro-inflammatory IFN response. By contrast, these
314 responses were abrogated in *Nod2*^{-/-} and *Mavs*^{-/-} mice derived BMDM.

315 Amongst enteric viruses commonly found in the microbiota, the Norovirus is considered as a
316 good candidate in the hypothesis of an environmental-driver in genetically susceptible hosts
317 at the origin of Crohn's disease onset. MNoV_CR6 strain was shown to induce colitis in
318 *Atg1611*^{HM} mice presenting defective autophagy in a DSS colitis model²¹.

319 Several PRR are implicated in viral sensing. MDA-5 and TLR3 have been shown to
320 participate in detection of either MNoV_1 or CW3¹¹. These are both strains which do not
321 persist *in vivo*, contrary to the S99 (*Berlin*) MNoV strain²⁶ that was used in our study.

322 Our *in vivo* data show significantly exacerbated inflammation when applying either 3% or 5%
323 DSS colitis protocol to WT mice. The excessive MNoV-S99 associated inflammatory
324 response was abrogated in *Nod2*^{-/-} mice or in BMDM derived from these mice showing
325 NOD2's implication in the pathogenesis and the viral sensing respectively. The genetic
326 ablation of NOD2 also improved the disease risk conferred by MNoV_CR6 in *Atg1611*^{HM}
327 mice (data not shown).

328 Hence, NOD2 dependent signalling adds a layer of regulation in viral sensing and finetunes
329 the immunopathology levels caused by the infection. While in our Norovirus + DSS model

330 knocking-down NOD2 prevents gut inflammation, it has the opposite effect with Influenza A
331 virus (IAV) infection in the lung of *Nod2*^{-/-} or *Ripk2*^{-/-} mice³². Indeed, the NOD2-RIPK2
332 signalling axis has been shown to downmodulate the NLRP3 dependent mitophagy activation
333 and the associated inflammatory response in the lung tissue of infected mice.

334 Noroviruses propagation or prolonged persistence is tightly regulated by the interplay
335 between several signalling pathways. MNoV_1 replication was shown to be inhibited in
336 macrophages following LPS mediated NF- κ B activation that in turn triggers IFN- β dependent
337 JAK-STAT antiviral activity³³. Interestingly, in our cellular models, in addition to the
338 phosphorylation of STAT1 that we observed when cells were infected with MNoV_S99
339 alone, the subsequent treatment with MDP induced an increased Nf κ B signalling pathway via
340 I κ B α activation. The synergistic activation of these two pro-inflammatory signalling
341 pathways results in the inhibition of the MNoV_S99 propagation on one hand and the
342 augmented production of the pro-inflammatory cytokine TNF α on the other hand. Hence, the
343 aggravated inflammatory pathology we observed in our DSS colitis model can be explained
344 by this NOD2-dependent dual signalling activation in MNoV_S99 infected mice. Similarly, *in*
345 *vitro* the signalling and cytokine responses were NOD2 dependent since they were only
346 observed in cultures derived from WT but not in *Nod2*^{-/-} mice, at least at a lower dose (Moi
347 0.1) of infection. At higher doses, NOD2-independent alternative mechanisms seem to be
348 active to promote Stat1 activation and TNF α production, but still at a lesser level than in WT
349 cells.

350 In conclusion, our study shows a NOD2 dependent mechanism that prevents low level
351 propagation of the persistent MNoV_S99 strain. When the noroviral infection is coupled with
352 digestive tract injury a positive signalling loop generates a potent pro-inflammatory response
353 that limits viral propagation.

354

355

356

357 **Methods:**

358 Unless otherwise indicated, all media and reagents were purchased from ThermoFischer
359 Scientific.

360

361 **Colitis mouse model and viral infection**

362 All animal experiments were approved by the local ethical committee n° CEEA-
363 2016030717519903. Age and gender related *Nod2*^{-/-} and wild type littermates C57BL/6J mice
364 (CDTA, Orléans, France) were housed 4-6 per cage, under strict pathogens-free environment.
365 Mice were gavaged with 10⁷ TCID₅₀PFU/mL of MNoV_S99 diluted in 200µl PBS or mock
366 treated with PBS only. 7 days post-infection, drinking water was substituted with a 3-5%
367 dextran sodium sulphate (DSS) (35,000-40,000 MW; TdB Consultancy) solution replaced
368 every 2 days for a total duration of 7 days.

369 For cohousing experiments, WT or *Nod2*^{-/-} (n = 5 each) C57BL/6J mice (CDTA, Orléans,
370 France) coming from non-specific pathogen free area were cohoused for 4 weeks. A group of
371 non-cohoused WT mice (n = 5) were kept separated. Stools were collected and kept frozen (-
372 80°C) until processed for RNA extraction and RT-qPCR measurement of viral genomes (see
373 below).

374 **Cells and virus**

375 Mouse leukemic monocyte macrophage cell line RAW264.7 were purchased from ECCAC
376 (Sigma-Aldrich) and maintained in Dulbecco's modified Eagle's medium (DMEM),
377 supplemented with 10% (v/v) foetal bovine serum, 1% penicillin/streptomycin and 1%
378 sodium pyruvate.

379 Bone marrow derived macrophages (BMDM) were isolated from femurs of wild-type, *Nod2*^{-/-}
380 or *Mavs*^{-/-} mice of C57BL/6J background³⁴. Briefly, bone marrow cells were flushed out of
381 the bones, red blood cells were lysed using a 160mM NH₄CL and 170mM Tris solution for 5
382 minutes at RT. 3 to 6.10⁶ viable cells were plated in non-cell-culture-treated petri dishes and
383 grown for 5-7 days in Iscove's modified Dulbecco's medium (IMDM), supplemented with
384 10% foetal bovine serum, 1% penicillin/streptomycin, 1% non-essential amino acid, 1%
385 sodium pyruvate, 1% glutamine, and 20% (v/v) conditioned-media from L929 cells.

386 Bone marrow derived dendritic cells were isolated similarly as BMDM cells. Then, 2.10⁶
387 viable cells were plated in non-cell-culture-treated petri dishes and grown for 7 days in RPMI
388 1640, supplemented with 10% FBS, 1% P/S, 1% L-glutamine, 1% HEPES and 20% (v/v)
389 conditioned-media from J558 cell line producing murine granulocyte monocyte colony
390 stimulating factor (GM-CSF).

391 Monocytes were isolated from bone marrow cells by using the mouse Monocyte Isolation Kit
392 (Miltenyi Biotec) and a QuadroMACS separator.

393 The MNoV-S99 strain (GenBank accession no. DQ911368) was provided by Prof. P. Maris
394 from ANSES Fougères Laboratory (France) and was propagated in RAW 264.7 cells.
395 Concentration of stock was determined by plaque assay. Mice were infected orally by pipette
396 with 3x10⁷ plaque forming units (PFU) resuspended in 25μL PBS.

397 For in vitro infection experiments, 3-5.10⁵ viable cells were seeded in 6 wells plates. The next
398 day, just before viral infection, cells were counted from 1 well to determine precisely the
399 multiplicity of infection (Moi). In the remaining wells medium was removed and replaced
400 with variable quantities of MNoV-S99 from a common viral stock in a final volume of 1 mL
401 fresh medium per well. Mock treated cells were incubated in parallel with matching quantities
402 of culture media from non-infected cells that was generated at the same time as viral stocks.

403 At various time-points after infection, supernatant was removed and cells were washed once
404 with PBS, before lysis in RIPA buffer for WB analysis or RLT buffer for total RNA
405 extraction (RNAeasy kit, Quiagen) for RT-qPCR experiments.

406

407 **Immunohistochemistry, ELISA, western blot and RT-qPCR analysis**

408 For immunohistochemistry analysis, formalin-fixed colon samples were embedded in
409 paraffin. 5µm sections were stained with H&E. Slides were imaged with an AxioPlan 2
410 (Zeiss) microscope and blindly scored for inflammation severity by two investigators as
411 previously described³⁵.

412 For ELISA analysis, briefly 1cm colon samples were recovered from mice, luminal content
413 was flushed with PBS, samples were cut opened and resuspended over-night in 250µl DMEM
414 supplemented with 1% P/S in 24 wells plate at 37°C. The following day, supernatants were
415 collected and stored at -80°C before cytokine measurement. TNFα and Interleukin-6 proteins
416 levels were measured specifically using pre-coated 96 wells ELISA plates (R&D System)
417 following manufacturers indications.

418 For TNFα ELISA from BMDC, 5.10^5 cells were plated in 24 wells plate and treated with
419 MNoV_S99's ssRNA (extracted with RNeasy Quiagen kit) ± MDP or MDP-DD (Invivogen)
420 over-night and supernatants were measured for TNFα levels.

421 For TNFα ELISA from BMDM, 2.10^5 cells were plated in 96 wells plate infected with
422 MNoV_S99 (Moi 0.1 or 1) for 6h prior to MDP treatment (10ug/mL) over-night and
423 supernatants were measured for TNFα levels.

424 For western blot analysis, total proteins from cell lysates were quantified by BCA protein
425 assay kit (Pierce), equalized amounts of proteins (10-20µg) were resolved by 4-15% gradient
426 SDS-PAGE gels and transferred to nitrocellulose membranes. Membranes were blocked in
427 0,05% PBS-Tween, 5% skimmed milk solution, before incubation subsequently with primary

428 and secondary antibodies diluted (see Table 1) in blocking solution. Following secondary
429 antibodies incubations, signals of interest were detected using a chemiluminescence reader
430 (ImageQuant™ Las 4000, GE Healthcare Life Sciences), images were processed and band
431 ROI were quantified with Image J software (NCBI). Mean band intensities \pm SD of protein of
432 interest were normalized to β -actin. Relative values to control mock-infected conditions were
433 compared between different experiments.

434 For *Nod2* quantification from MNoV_S99 infected BMDM or RAW264.7 cells, total RNA
435 extraction was performed using the RNeasy Mini Kit (Qiagen). One μ g of RNA was reversed
436 transcribed in the presence of 2.5mM of oligo-dT using the Reverse Transcriptor kit (Roche)
437 following the manufacturer's instructions. 75ng of cDNAs were amplified using Q5 High-
438 Fidelity 2X Master Mix (New England BioLabs). Primers used in PCR amplification are
439 available upon request.

440 *Actb* was used as an internal reference gene in order to normalize the transcript levels.
441 Relative mRNA levels ($2^{-\Delta\Delta Ct}$) were determined by comparing (a) the PCR cycle thresholds
442 (Ct) for *Nod2* and *Actb* (ΔCt) and (b) ΔCt values for treated and control groups ($\Delta\Delta Ct$).

443 MNoV_S99 load was determined by measuring MNoV genome copy numbers by RT-qPCR
444 analysis as previously described³⁶. Briefly, total RNA was extracted from BMDM cell
445 cultures using the RNeasy Mini Kit (Qiagen) and from stool using QIAamp Viral RNA Kit
446 (Qiagen). 5 μ L of RNA were used per reaction of RT-qPCR. Viral genome levels were
447 determined using the Takyon™Dry No Rox One-Step RT Probe Mastermix (Eurogentec).
448 Viral genomes were specifically amplified using the
449 Fwd_5'GTGCGCAACACAGAGAAAACG3' and Rev_5'CGGGCTGAGCTTCCTGC3'
450 primers that target MNoV ORF1 region combined to a TaqMan probe using the Stratagene
451 Mx3005P (Agilent Technologies). The quantification of viral genome copies was obtained using a

452 standard curve with serial dilutions of the plasmid pMNoV1 corresponding to the full genome of
453 MNoV1 (Dr Christiane Wobus, University of Michigan, USA).

454

455 ***NOD2*^{GFP} immunohistochemistry imaging**

456 *NOD2*^{GFP} mice³⁷ in the C57BL/6 background were maintained at the Institut Pasteur Central
457 Animal facility. We used heterozygous *NOD2*^{GFP} mice since the presence of one functional
458 copy of *NOD2* ensures that physiological responses dependent on functional NOD2 are not
459 impaired. Heterozygous *NOD2*^{GFP} female mice (8-12 weeks of age) were sacrificed and
460 several centimetres of the distal ileum were removed, opened longitudinally and washed in
461 PBS. The tissue was spread flat over a 4% w/v LMP agarose (Merck) pad and fixed with 4%
462 v/v paraformaldehyde (VWR). The ileal tissue was then embedded in a 4% LMP agarose
463 block and cut into 200µm-thick sections using a Microm HM 650 V Vibration microtome.

464 For staining, tissues were blocked, permeabilized and marked with an anti-GFP (rabbit
465 polyclonal antibody A-11122) primary antibody and secondary Alexa Fluor 488 goat anti-
466 rabbit antibody. Tissues sections were counter stained with DAPI (1µg/mL, BD Biosciences)
467 and Phalloidin- iFluor 647 (1:200 dilution, Abcam and mounted using ProLong Gold
468 Antifade reagent. Confocal acquisitions were performed using a Leica HyD SP5 confocal
469 microscope. Image analysis was performed using Icy version 2.4.2.0³⁸.

470

471 **References:**

- 472 1. Cadwell, K. Expanding the role of the virome: commensalism in the gut. *J. Virol.* **89**,
473 1951–1953 (2015).
- 474 2. Norman, J. M. *et al.* Disease-specific alterations in the enteric virome in inflammatory
475 bowel disease. *Cell* **160**, 447–460 (2015).
- 476 3. Pfeiffer, J. K. & Virgin, H. W. Viral immunity. Transkingdom control of viral
477 infection and immunity in the mammalian intestine. *Science* **351**, aad5872 (2016).
- 478 4. Ettayebi, K. *et al.* Replication of human noroviruses in stem cell-derived human
479 enteroids. *Science* **353**, 1387–1393 (2016).
- 480 5. Estes, M. K. *et al.* Human Norovirus Cultivation in Nontransformed Stem Cell-
481 Derived Human Intestinal Enteroid Cultures: Success and Challenges. *Viruses* **11**, E638
482 (2019).

- 483 6. Ludwig-Begall, L. F., Mauroy, A. & Thiry, E. Noroviruses-The State of the Art,
484 Nearly Fifty Years after Their Initial Discovery. *Viruses* **13**, 1541 (2021).
- 485 7. Newman, K. L. & Leon, J. S. Norovirus immunology: Of mice and mechanisms. *Eur.*
486 *J. Immunol.* **45**, 2742–2757 (2015).
- 487 8. Wobus, C. E. *et al.* Replication of Norovirus in cell culture reveals a tropism for
488 dendritic cells and macrophages. *PLoS Biol.* **2**, e432 (2004).
- 489 9. Thackray, L. B. *et al.* Murine noroviruses comprising a single genogroup exhibit
490 biological diversity despite limited sequence divergence. *J. Virol.* **81**, 10460–10473 (2007).
- 491 10. Thorne, L. G. & Goodfellow, I. G. Norovirus gene expression and replication. *J. Gen.*
492 *Virol.* **95**, 278–291 (2014).
- 493 11. McCartney, S. A. *et al.* MDA-5 recognition of a murine norovirus. *PLoS Pathog.* **4**,
494 e1000108 (2008).
- 495 12. Wang, P. *et al.* Nlrp6 regulates intestinal antiviral innate immunity. *Science* **350**, 826–
496 830 (2015).
- 497 13. Chamailard, M., Girardin, S. E., Viala, J. & Philpott, D. J. Nods, Nalps and Naip:
498 intracellular regulators of bacterial-induced inflammation. *Cell. Microbiol.* **5**, 581–592
499 (2003).
- 500 14. Sabbah, A. *et al.* Activation of innate immune antiviral responses by Nod2. *Nat.*
501 *Immunol.* **10**, 1073–1080 (2009).
- 502 15. Kim, Y.-G. *et al.* Viral infection augments Nod1/2 signaling to potentiate lethality
503 associated with secondary bacterial infections. *Cell Host Microbe* **9**, 496–507 (2011).
- 504 16. Karst, S. M., Wobus, C. E., Lay, M., Davidson, J. & Virgin, H. W. STAT1-dependent
505 innate immunity to a Norwalk-like virus. *Science* **299**, 1575–1578 (2003).
- 506 17. Mumphrey, S. M. *et al.* Murine norovirus 1 infection is associated with
507 histopathological changes in immunocompetent hosts, but clinical disease is prevented by
508 STAT1-dependent interferon responses. *J. Virol.* **81**, 3251–3263 (2007).
- 509 18. Nice, T. J., Strong, D. W., McCune, B. T., Pohl, C. S. & Virgin, H. W. A single-
510 amino-acid change in murine norovirus NS1/2 is sufficient for colonic tropism and
511 persistence. *J. Virol.* **87**, 327–334 (2013).
- 512 19. Nice, T. J. *et al.* Interferon- λ cures persistent murine norovirus infection in the
513 absence of adaptive immunity. *Science* **347**, 269–273 (2015).
- 514 20. Hwang, S. *et al.* Nondegradative role of Atg5-Atg12/ Atg16L1 autophagy protein
515 complex in antiviral activity of interferon gamma. *Cell Host Microbe* **11**, 397–409 (2012).
- 516 21. Cadwell, K. *et al.* Virus-plus-susceptibility gene interaction determines Crohn’s
517 disease gene Atg16L1 phenotypes in intestine. *Cell* **141**, 1135–1145 (2010).
- 518 22. Travassos, L. H. *et al.* Nod1 and Nod2 direct autophagy by recruiting ATG16L1 to the
519 plasma membrane at the site of bacterial entry. *Nat. Immunol.* **11**, 55–62 (2010).
- 520 23. Maloy, K. J. & Powrie, F. Intestinal homeostasis and its breakdown in inflammatory
521 bowel disease. *Nature* **474**, 298–306 (2011).
- 522 24. Hugot, J. P. *et al.* Association of NOD2 leucine-rich repeat variants with susceptibility
523 to Crohn’s disease. *Nature* **411**, 599–603 (2001).
- 524 25. Hampe, J. *et al.* A genome-wide association scan of nonsynonymous SNPs identifies a
525 susceptibility variant for Crohn disease in ATG16L1. *Nat. Genet.* **39**, 207–211 (2007).
- 526 26. Niendorf, S., Klemm, U., Mas Marques, A., Bock, C.-T. & Höhne, M. Infection with
527 the Persistent Murine Norovirus Strain MNV-S99 Suppresses IFN-Beta Release and
528 Activation of Stat1 In Vitro. *PloS One* **11**, e0156898 (2016).
- 529 27. Hrdý, J. *et al.* Lactobacillus reuteri 5454 and Bifidobacterium animalis ssp. lactis 5764
530 improve colitis while differentially impacting dendritic cells maturation and antimicrobial
531 responses. *Sci. Rep.* **10**, 5345 (2020).
- 532 28. Wilen, C. B. *et al.* Tropism for tuft cells determines immune promotion of norovirus

- 533 pathogenesis. *Science* **360**, 204–208 (2018).
- 534 29. Hold, G. L. *et al.* Role of the gut microbiota in inflammatory bowel disease
535 pathogenesis: what have we learnt in the past 10 years? *World J. Gastroenterol.* **20**, 1192–
536 1210 (2014).
- 537 30. Kim, D. H. & Cheon, J. H. Pathogenesis of Inflammatory Bowel Disease and Recent
538 Advances in Biologic Therapies. *Immune Netw.* **17**, 25–40 (2017).
- 539 31. Simmons, A. Crohn's disease: Genes, viruses and microbes. *Nature* **466**, 699–700
540 (2010).
- 541 32. Lupfer, C. *et al.* Receptor interacting protein kinase 2-mediated mitophagy regulates
542 inflammasome activation during virus infection. *Nat. Immunol.* **14**, 480–488 (2013).
- 543 33. Yu, P., Li, Y., Wang, Y., Peppelenbosch, M. P. & Pan, Q. Lipopolysaccharide restricts
544 murine norovirus infection in macrophages mainly through NF- κ B and JAK-STAT signaling
545 pathway. *Virology* **546**, 109–121 (2020).
- 546 34. Michallet, M.-C. *et al.* TRADD protein is an essential component of the RIG-like
547 helicase antiviral pathway. *Immunity* **28**, 651–661 (2008).
- 548 35. Wirtz, S. *et al.* Chemically induced mouse models of acute and chronic intestinal
549 inflammation. *Nat. Protoc.* **12**, 1295–1309 (2017).
- 550 36. Hwang, S. *et al.* Murine norovirus: propagation, quantification, and genetic
551 manipulation. *Curr. Protoc. Microbiol.* **33**, 15K.2.1-61 (2014).
- 552 37. Barreau, F. *et al.* CARD15/NOD2 is required for Peyer's patches homeostasis in mice.
553 *PloS One* **2**, e523 (2007).
- 554 38. de Chaumont, F. *et al.* Icy: an open bioimage informatics platform for extended
555 reproducible research. *Nat. Methods* **9**, 690–696 (2012).
- 556

557 **Acknowledgments:**

558 For the *NOD*^{GFP} tissue imaging, we thank the UTechS PBI, a member of the France–
559 BioImaging infrastructure network supported by the French National Research Agency
560 (ANR-10-INSB-04, Investissement d'Avenir program) for microscope usage and assistance.

561 We thank the members of the Institut Pasteur Central Animal Facility for their assistance with
562 animal studies. I.G.B. laboratory was supported by Investissement d'Avenir program,
563 Laboratoire d'Excellence "Integrative Biology of Emerging Infectious Diseases" (ANR-10-
564 LABX-62-IBEID), by the Investissement d'Avenir program (RHU Torino Lumière ANR-16-
565 RHUS-0008), by the French National Research Agency (ANR-16-CE15-0021) and by R&D
566 grants from Danone and MEIJI.

567 M.C. was supported by grants from the Fondation pour la Recherche Médicale
568 (DEQ20130326475) and the European Union's European Regional Development Fund. We
569 thank T. Durand and MP. Fourmaux for excellent technical assistance.

570

571 **Authors' contribution.** G.M. and M.T. performed the majority of the experimental
572 procedures. T.G. contributed to the preclinical studies in mice. M.D., T.G. and O.B.
573 performed RT-qPCR and ELISA analysis. M.D. contributed to histological analysis of colon
574 sections. E.W. performed viral genome quantification by RT-qPCR. R.W. and I.G.B.
575 performed histological analysis of tissue sections from NOD2- β -Gal reporter mice. All
576 authors contributed to interpretation of raw data and critically reviewed and/or modified the
577 manuscript. G.M. and M.C. conceived, designed and wrote the paper.

578

579 **Figures legends:**

580 **Figure 1: MNoV_S99 aggravates inflammation in DSS-induced colitis**

581 **A)- In vivo experimental design, C57BL/6J mice were orally gavaged with PBS or MNoV_S99 (10^7**
582 **TCID₅₀PFU/mL), 7 days later, all the mice were given DSS in drinking water for a week. Mice were**
583 **weighed daily for weight loss comparison. B)- 3% DSS-induced colitis ± MNoV_S99 (n = 6). C)- 5%**
584 **DSS-induced colitis ± MNoV_S99 (n = 6). In B) and C), statistical differences were determined by 2**
585 **ways ANOVA test, * p < 0.05, ** p < 0.01, *** p < 0.001. D)- Representative images from H&E**
586 **staining of colon sections from mock-treated (Control) or 3% DSS ± MNoV_S99 treated mice. Insets**
587 **showing higher magnifications from each image are presented next to each image. E)- Muscle wall**
588 **thickness was determined with Image J from colon section images. Percentages of increase are plotted**
589 **after baseline subtraction relatively to the values obtained from Control mice (n = 6). F)- Histological**
590 **intestinal epithelial inflammation scores comparison between Control, 3% or 5% DSS ± MNoV_S99**
591 **treated mice (n = 6). G)- Colon length comparison between Control and 5% DSS ± MNoV_S99**
592 **treated mice H- IL6 secretion levels from colon explants from mock or 5% DSS ± MNoV_S99 treated**
593 **mice (n = 6). Statistical differences were determined with Student's t-Test in E, F, G and H.**

594
595
596

597 **Figure 2: MNoV_S99 associated inflammation is NOD2 dependent**

598 **Weight loss comparison in A)- 3% DSS-induced colitis ± MNoV_S99 in WT mice (n=6) and B)- in**
599 ***Nod2*^{-/-} mice (n=6), statistical differences were determined by 2 ways ANOVA test, * p < 0,05, ** p <**
600 **0,01, *** p < 0,001. C)- Representative images of H&E staining of colon sections from mice in A).**
601 **Insets showing higher magnifications are presented below each image. D)- Percentages of increase of**
602 **muscle wall thickness from colon section images are plotted after baseline subtraction relatively to the**
603 **values obtained from WT mice treated only with DSS (n = 6), statistical differences were determined**
604 **with Student's t-Test.**

605
606
607

608 **Figure 3: MNoV_S99 associated pro-inflammatory signalling is Nod2 and MAVS-dependent in**
609 **myeloid lineage cells**

610 **A)- Representative image showing an intestinal villus from a *Nod2*^{GFP} mouse (GFP is shown in green,**
611 **Phalloidin in grey and DAPI in blue); scale bare represents 50µm. B)- Representative western blot**
612 **showing STAT1 signalling pathway activation after 1h infection (Moi 1) with the mentioned MNoV**
613 **strains in BMDM. Below are shown quantification of pSTAT1 bands intensities normalized to β-actin**
614 **and relative to mock-infected cells (n = 3, mean ± SEM), statistical differences were determined by 1**
615 **way ANOVA test * p < 0,05, ** p < 0,005. C)- STAT1 activation in response to MNoV_S99 (Moi 1**
616 **or 5) in BMDM from WT vs *Nod2*^{-/-} infected for 30 or 60 minutes. The lower panel shows**
617 **quantification of pSTAT1, bands intensities normalized to β-actin and relative to mock-infected cells**
618 **(n = 3, mean ± SEM). Statistical differences were determined by 2 ways ANOVA test * p < 0,05. D)-**
619 **STAT1 activation in response to MNoV_S99 (Moi 0.1) in WT or *Nod2*^{-/-} BMDM infected for 24h.**
620 **Relative quantification of pSTAT1 (n = 3, mean ± SEM) is shown in the lower panel, statistical**
621 **differences were determined by 2 ways ANOVA test *** p < 0,0005. E)- STAT1 activation in**
622 **response to MNoV_S99 (Moi 0.1) in BMDM from WT vs *Mavs*^{-/-} infected for 60 minutes. Relative**
623 **quantification of pSTAT1 (n = 4, mean ± SEM) are shown below. The lower panel shows the mock vs**
624 **Moi 0.1 infected cells quantification of pSTAT1. Statistical differences were determined by 2 ways**
625 **ANOVA test * p < 0,05.**

626

627

628

629

630 **Figure 4: NOD2 dependent pro-inflammatory signalling associated with MNoV_S99 infection**
 631 **and bacterial MDP**

632 Quantification of *Nod2* mRNA levels measured by RT-qPCR in **A)**- in Raw264.7 cells infected with
 633 MNoV_S99 (Moi 0.1 or 1, **for 24h**) and in **B)**- in BMDM from WT mice (Moi 0.1, **for 24h**)
 634 normalized to *ActB* and relative to mock-infected cells (n = 3). **C)**- MNoV genome quantification from
 635 WT and *Nod2*^{-/-} BMDM cells infected with MNoV_S99 (Moi 0.1 for 24h) (n = 3). **D)**- Representative
 636 western blot showing STAT1 and IκBα signalling pathways modulation in cell lysates from
 637 monocytes that were either infected with MNoV_S99 (Moi 5, 2h), treated with MDP (10ng/mL, 2h),
 638 or a combination of both. **E)**- Quantification and comparison of pSTAT1 and pIκBα signals between
 639 MNoV_S99 infected alone cells or in combination with MDP (10ng/mL, 2h), (n = 3), with the band
 640 intensity being normalized to β-actin and relative to mock-treated cells. **F)** **Mouse norovirus genome**
 641 **quantification from stool of non-cohoused WT mice (WT), *Nod2*^{-/-} mice cohoused with WT mice**
 642 **(CH-WT_{Nod2}^{-/-}) or WT mice cohoused with *Nod2*^{-/-} (CH-*Nod2*^{-/-}-WT) (n=5 per group). **G)** TNFα
 643 production by BMDM cells infected with MNoV_S99 (Moi 0.1 or 1) for 6h, prior to being treated
 644 with MDP (10μg/mL) overnight. **H)** TNFα production by BMDC subjected to MNoV_S99's ssRNA
 645 (10μg/mL) alone, or supplemented with either MDP (1μg/mL) or MDP-DD (1μg/mL) overnight. In all
 646 experiments statistical differences were analyzed with Student's t Test.**

647
 648
 649

650 **Supplementary Figures**

651

652 **Supplementary Figure 1: Analysis of MNoV_S99 associated NOD2 dependent inflammation**
 653 **measurements from mice showed in Figure 2**

654 **A)** Colon length comparison from WT and *Nod2*^{-/-} 3% DSS ± MNoV_S99 treated mice, statistical
 655 differences were determined with a t-Test, * p <0,02. **B)**- Histological scores comparison between WT
 656 and *Nod2*^{-/-} ± MNoV_S99 treated mice, statistical differences were determined with a t-Test, * p
 657 <0,05. **C)**- **TNFα production of explants (ON) from WT and *Nod2*^{-/-} 3% DSS ± MNoV_S99 treated**
 658 **mice was measured by ELISA.**

659

660 **Supplementary Figure 2: MNoV_S99 associated pro-inflammatory signalling pathways**
 661 **activation**

662 Representative western blot showing STAT1, IκBα, AKT and ERK signalling pathways' modulation
 663 in cell lysates from Raw264.7 that were either infected with MNoV_S99 (Moi 1) for various times or
 664 mock treated for 60 min. β-actin was used as loading control.

665

666 **Tables:**

Table1: Antibodies used for Western Blotting		
Primary antibodies	Dilution	Supplier
anti-phosphoStat1 (Tyr 701) (58D6) (85kDa)	1/1000	Cell Signaling Technology
anti-Stat1(D1K9Y)(85kDa)	1/1000	
anti-phosphoIκBα (Ser32/36) (5A5) (40kDa)	1/1000	
anti-IκBα (44D4) (39kDa)	1/1000	
anti-phosphoAKT (Ser473) (D9E) (60kDa)	1/1000	
anti-AKT (60kDa)	1/1000	
anti-phospho44/42 MAPK (Erk1/2) (Trh202/Tyr204) (197G2) (42, 44 kDa)	1/1000	
anti-p44/42 (Erk1/2) (42, 44 kDa)	1/1000	
anti-βactin (45kDa)	1/500	
Secondary antibodies	Dilution	
anti-Rabbit_HRP (#711-035-152)	1/5000	Jackson
anti-Mouse_HRP (#115-005-003)	1/5000	Laboratories

667